Axsome Therapeutics
AXSM
AXSM
173 hedge funds and large institutions have $791M invested in Axsome Therapeutics in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 63 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
4% more funds holding
Funds holding: 167 → 173 (+6)
0.22% more ownership
Funds ownership: 49.47% → 49.69% (+0.22%)
35% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 63
Holders
173
Holding in Top 10
3
Calls
$94.9M
Puts
$64.8M
Top Buyers
| 1 | +$31.2M | |
| 2 | +$26.9M | |
| 3 | +$7.52M | |
| 4 |
D.E. Shaw & Co
New York
|
+$6.43M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$5.4M |
Top Sellers
| 1 | -$14.8M | |
| 2 | -$12.7M | |
| 3 | -$5.01M | |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$4.54M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.39M |